Immediate Impact

54 standout
Sub-graph 1 of 24

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Heterocyclic amino acids-based green and sustainable corrosion inhibitors: Adsorption, bonding and corrosion control
2024 Standout
2 intermediate papers

Works of Luckson Mathieu being referenced

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
2018

Author Peers

Author Last Decade Papers Cites
Luckson Mathieu 237 272 82 150 12 492
Qiuxia Dong 191 314 70 127 14 495
Ann W. Gramza 175 193 70 134 21 535
Yunhong Tian 203 289 81 153 19 540
Israel Cañadas 207 283 43 178 11 476
Rebecca Tay 203 397 67 83 21 496
Tahsin M. Khan 355 333 45 268 19 573
Andrea Ravelli 246 284 35 198 15 533
Pranshu Bansal 220 290 49 118 21 508
Xiaoling Ou 395 271 91 178 12 550
Matthew Robson 318 280 70 229 13 549

All Works

Loading papers...

Rankless by CCL
2026